Startups
Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.
Overview
Location
Israel, Center District, Nes Ziona
Employees
11-50
Phone
+972 73-797-1601
Total raised
$16.95M
Founded date
2009
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 25, 2021 | Funding round | $6.8M | |
| Oct 2, 2018 | Funding round | $5.15M |
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 23, 2025 | - | On October 21, 2025, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the trading of the Company on the Nasdaq Capital Market after completion of the Merger, under NLS's new name, Newce... |
| Jul 3, 2025 | Fresh funding to expedite NLS Pharma’s merger process | In accordance with the second closing, NLS Pharmaceutics Ltd agreed to issue 606,061 preferred shares (or equivalent) at a conversion price of $1.65 per share, representing a 10% premium to the market share price on the date the original a... |
| Apr 9, 2025 | NLS Pharma raises $3 million equity funding | NLS Pharma IS a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, announced the closing of a $2 million equity financing of preferred shares at a stated va... |
| Feb 5, 2025 | NLS Pharma gets go-ahead for reverse merger | Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics plans to merge with Kadimastem, a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neu... |
| Dec 13, 2021 | Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority | (via NewsDirect) Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 mill... |
| Dec 13, 2021 | Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority | DGAP-News: Kadimastem Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority 13.12.2021 / 13:00 The issuer is solely responsible for the content of this announcement. Kadimastem Ltd. (TASE: KDST),... |
| Oct 26, 2021 | Kadimastem : Raises $5 million In Private Placement | (via NewsDirect) Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today a NIS 16.1 million ($5 million) private placement, led by funds Clover Wolf Capital and Alpha Capital Anstalt and with the additional inve... |
| Oct 26, 2021 | PRESS RELEASE : Kadimastem Raises USD5 million In Private Placement | DGAP-News: Kadimastem Kadimastem Raises USD5 million In Private Placement 2021-10-26 / 07:49 The issuer is solely responsible for the content of this announcement. ----------------------------------------------------------------------------... |
| Oct 26, 2021 | Kadimastem : Raises $5 million In Private Placement | DGAP-News: Kadimastem Kadimastem Raises $5 million In Private Placement 26.10.2021 / 07:49 The issuer is solely responsible for the content of this announcement. Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced... |
Show more
Reviews 0
FAQ about Kadimastem Ltd.
When was Kadimastem Ltd. founded?
Kadimastem Ltd. was founded in 2009.
How much funding has Kadimastem Ltd. raised?
Kadimastem Ltd. has raised $16.95M in total across 3 funding rounds.
What funding rounds has Kadimastem Ltd. raised?
Parsers VC lists 3 funding rounds of Kadimastem Ltd., among them a funding round of $6.8M on Apr 25, 2021 and a funding round of $5.15M on Oct 2, 2018.
What has the press written about Kadimastem Ltd.?
Parsers VC has collected 15 articles mentioning Kadimastem Ltd., among them “Fresh funding to expedite NLS Pharma’s merger process” (Jul 3, 2025) and “NLS Pharma raises $3 million equity funding” (Apr 9, 2025).
Is Kadimastem Ltd. still active?
Yes, Kadimastem Ltd. is active; its latest activity on Parsers VC dates from Nov 4, 2025.